| Original language | English (US) |
|---|---|
| Pages (from-to) | 113-132 |
| Number of pages | 20 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2022 |
Keywords
- Glioblastoma
- Glioma
- H3K27M mutant glioma
- IDH wild-type
- Pilocytic astrocytoma
- Pleomorphic xanthoastrocytoma
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Hematology/Oncology Clinics of North America, Vol. 36, No. 1, 02.2022, p. 113-132.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma
AU - Galanis, Evanthia
AU - Wen, Patrick Y.
AU - de Groot, John F.
AU - Weller, Michael
N1 - Funding Information: Dr E. Galanis reports general consulting with MedImmune, Inc. (compensation to Mayo); Advisory Board member for Gradalis, Inc. and Kiyatec, Inc. (personal compensation) and Agios Pharmaceuticals (compensation to Mayo); and grant/research/clinical trial funding to her institution from MedImmune, Tracon, Genentech, and Bristol-Myers Squibb. Dr J.F. de Groot reports paid consulting with Del Mar Pharmaceuticals (BC) Ltd, Samus Therapeutics, Inc., Insightec, Bioasis Technologies, Inc., Magnolia Innovation, LLC, Monteris Medical Corporation, Karyopharm Therapeutics Inc.; grant/research support from CarThera and HaiHe Pharma; advisory board membership Samus Therapeutics, Inc., Cure Brain Cancer Foundation, Merck Sharp & Dohme Co., Sapience Therapeutics; stock ownership in Ziopharm Oncology and WuXi Biologics; and company employment (spouse) at Ziopharm Oncology. Dr P.Y. Wen receives research support from Agios, AstraZeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Vascular Biogenics, VBI Vaccines; Advisory Board member for Agios, Astra Zeneca, Bayer, Black Diamond, Boston Pharmaceuticals, CNS Pharmaceuticals, Elevate Bio Immunomic Therapeutics, Imvax, Karyopharm, Merck, Novartis, Nuvation Bio, Vascular Biogenics, VBI Vaccines, Voyager, QED, Celularity, Sapience. Dr M. Weller has received research grants from Abbvie, Adastra, Apogenix, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, and Quercis, and honoraria for lectures or advisory board participation or consulting from Abbvie, Adastra, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, MSD, Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen, Roche, Tocagen, and yMabs.
PY - 2022/2
Y1 - 2022/2
KW - Glioblastoma
KW - Glioma
KW - H3K27M mutant glioma
KW - IDH wild-type
KW - Pilocytic astrocytoma
KW - Pleomorphic xanthoastrocytoma
UR - http://www.scopus.com/inward/record.url?scp=85118328985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118328985&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2021.08.007
DO - 10.1016/j.hoc.2021.08.007
M3 - Review article
C2 - 34756799
AN - SCOPUS:85118328985
SN - 0889-8588
VL - 36
SP - 113
EP - 132
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -